Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска
СтатьяИскать документыПерейти к записи. 2020; № 7: 56–65. DOI:10.21518/2079-701X-2020-7-56-65
Диагностика и лечение ранних стадий диабетической полинейропатии
Искать документыПерейти к записи[1]
Искать документыПерейти к записи[1]
Искать документыПерейти к записи[1]
Аффилированные организации
[1]Искать документыПерейти к записи
Аннотация
Диабетическая полинейропатия является самым ранним и наиболее частым осложнением сахарного диабета. Диабетическая полинейропатия может развиваться на ранних стадиях нарушения углеводного обмена, более того, дистальная полинейропатия может развиваться и у пациентов с метаболическим синдромом, не имеющих нарушений углеводного обмена. Гипергликемия является важнейшим, но не единственным фактором риска развития и прогрессии диабетической полинейропатии. Поражение периферической нервной системы при преддиабете и на начальных этапах сахарного диабета преимущественно затрагивает тонкие нервные волокна, что обуславливает достаточно частое развитие нарушений со стороны вегетативной нервной системы. Так, уже на момент диагностики сахарного диабета 1-го и 2-го типов кардиальная автономная нейропатия диагностируется у 5–7,7[%]. Скрининг диабетической полинейропатии рекомендован не только при сахарном диабете 1-го типа длительностью 5 лет и более и сахарном диабете 2-го типа с момента диагноза, но и среди симптомных пациентов с преддиабетом. Для ранней диагностики диабетической полинейропатии могут использоваться как рутинные тесты оценки периферической чувствительности, так и специализированные методики (симпатические кожные реакции, биопсия кожи, конфокальная корнеальная микроскопия, количественные сенсорные тесты) и валидизированные опросники (шкала Юта для диагностики ранних проявлений нейропатии), акцентированные на оценке функции тонких нервных волокон. Для диагностики ранней диабетической полинейропатии могут быть использованы и неэлектрофизиологические исследования: соноэластография периферических нервов, оптическая когерентная томография, МРТ-нейрография, спиральная позитронно-эмиссионная КТ с 123 йод-метайодобензилгуанидином. Ранняя диагностика диабетической полинейропатии крайне важна, т. к. изменение образа жизни, расширение физической активности способно замедлить развитие данного осложнения. Соотношение выраженности оксидативного стресса и активности антиоксидантной защиты рассматривается как потенциальный механизм раннего поражения периферической нервной системы при гипергликемии и как возможная цель терапевтического воздействия. В обзоре обсуждаются вопросы эпидемиологии, диагностики и потенциальные терапевтические стратегии ранней диабетической полинейропатии.
Ключевые слова
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Рубрики Mesh
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Искать документыПерейти к записи
Литература

Dedov I.I., Kalashnikova M.F., Belousov D.Y., Kolbin A.S., Rafalskiy V.V., Cheberda A.E., Kantemirova M.A., Zakiev V.D., Fadeyev V.V. Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT- Т2DM). Sakharni Diabet = Diabetes Mellitus. 2017;20(6):403–419. (In Russ.) doi: 10.14341/DM9278.
DOI: 10.14341/DM9278

Malik R.A. Which test for diagnosing early diabetic neuropathy? Diabetes. 2014;63(7):2206–2208. doi: https://doi.org/10.2337/db14-0492..
DOI: 10.2337/db14-0492

Vinik A.I., Casellini C., Nevoret M.L. Alternative quantitative tools in the assessment of diabetic peripheral and autonomic neuropathy. Int Rev Neurobiol. 2016;127:235–285. doi: 10.1016/bs.irn.2016.03.010..
DOI: 10.1016/bs.irn.2016.03.010

Tesfaye S., Boulton A.J.M., Dyck P.J., Freeman R., Horowitz M., Kempler P. et al. Diabetic neuropathies: update on definitions, diagnostic care, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–2293. doi: 10.2337/dc10-1303..
DOI: 10.2337/dc10-1303

Pop-Busui R., Boulton A.J.M., Feldman E.L., Bril V., Freeman R., Malik R.A., Sosenko J.M., Ziegler D. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. doi: 10.2337/dc16-2042.
DOI: 10.2337/dc16-2042

Dyck P.J., Albers J.W., Andersen H., Arezzo J.C., Biessels G.J., Bril V. et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011;27(7):620–628. doi: 10.1002/dmrr.1226..
DOI: 10.1002/dmrr.1226

Won J.C., Park T.S. Recent advances in diagnostic strategies for diabetic peripheral neuropathy. Endocrinol Metab. 2016;31(2):230–238. doi: 10.3803/EnM.2016.31.2.230..
DOI: 10.3803/EnM.2016.31.2.230

Rajabally Y.A. Neuropathy and impaired glucose tolerance: un updated review of the evidence. Acta Neurol Scand. 2011;124(1):1–8. doi: 10.1111/j.1600-0404.2010.01425.x..
DOI: 10.1111/j.1600-0404.2010.01425.x

Celikbilek A., Tank N., Sabah S., Borecki E., Akyol L., Ak H. et al. Elevated neurofilament light chain (NLC) mRNA levels in pre-diabetic peripheral neuropathy. Mol Biol Rep. 2014;41:4017–4022. doi: 10.1007/s11033-014-3270-y..
DOI: 10.1007/s11033-014-3270-y

Han L., Ji L., Chang J., Wen J., Zhao W., Shi H. et al. Peripheral neuropathy is associated with insulin resistance independent of metabolic syndrome. Diabetol Metab Syndr. 2015;3(7):14. doi: 10.1186/s13098-015-0010-y..
DOI: 10.1186/s13098-015-0010-y

Smith A.G., Rose K., Singleton J.R. Idiopathic neuropathy patients are at high risk for metabolic syndrome. J Neurol Sci. 2008;273(1–2):25–28. doi: 10.1016/j.jns.2008.06.005..
DOI: 10.1016/j.jns.2008.06.005

Spijkerman A.M., Dekker J.M., Nijpels G. et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study. Diabetes Care. 2003;26(9):2604–2608. doi: 10.2337/diacare.26.9.2604..
DOI: 10.2337/diacare.26.9.2604

England J.D., Gronseth G.S., Franklin G., Miller R.G., Asbury A.K., Carter G.T. et al. Distal symmetric polyneuropathy: a definition for clinical research: Report of the American Academy of Neurology, the American Association of Electrodiagnostic medicine, and the American Academy of Physical medicine and Rehabilitation. Neurology 2005;64(2):199–207. doi: 10.1212/01.WNL.0000149522.32823.EA..
DOI: 10.1212/01.WNL.0000149522.32823.EA

American Diabetes Association. Standards of Medical Care in Diabetes. Microvascular complications and foot care. Diabetes Care. 2017;40(1):88–98. doi: 10.2337/dc17-S013..
DOI: 10.2337/dc17-S013

Alam U. Prevalence of Peripheral Neuropathy in Prediabetes. Diabetes. 2018;67(Suppl. 1):552-P. doi: 10.2337/db18-552-P..
DOI: 10.2337/db18-552-P

Lee C.C., Perkins B.A., Kayaniyil S., Harris S.B., Retnakaran R., Gerstein H.C., Zinman B., Hanley A.J. Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. Diabetes Care. 2015;38(50):793–800. doi: 10.2337/dc14-2585..
DOI: 10.2337/dc14-2585

Dyck P.J. Detection, characterization and staging of polyneuropathy: assessed in diabetics. Muscle Nerve. 1988;11(1):21–32. doi: 10.1002/mus.880110106..
DOI: 10.1002/mus.880110106

Russell J.W., Zilliox L.A. Diabetic Neuropathies. Continuum (Minneap Minn). 2014;20(5):1226–140. doi: 10.1212/01.CON.0000455884.29545.d2..
DOI: 10.1212/01.CON.0000455884.29545.d2

Feng Y., Schossler P.J., Sumpio B.E. The Semmes-Weinstein monofi lament is a signifi cant predictor of the risk of foot ulceration and amputation in patients with diabetes mellitus. J Vasc Surg 2011;53(1):220–226. doi: 10.1016/j.jvs.2010.06.100..
DOI: 10.1016/j.jvs.2010.06.100

Bril V., Perkins B., Toth C. Canadian Diabetes Association Clinical Practice Guidelines. Neuropathy. Can J Diabetes. 2013;37(1):142–144. doi: 10.1016/j.jcjd.2013.01.039..
DOI: 10.1016/j.jcjd.2013.01.039

Dros J., Wewerinke A., Bindels P.J., von Weert H.C. Accuracy of monofilament testing to diagnose peripheral neuropathy: a systematic review. Ann Fam Med. 2009;7(6):555–558. doi: 10.1370/afm.1016..
DOI: 10.1370/afm.1016

Feldman E.L., Stevens M.J., Thomas P.K., Brown M.B., Canal M., Greene D.A. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17(11):1281–1289. doi: 10.2337/diacare.17.11.1281..
DOI: 10.2337/diacare.17.11.1281

Herman W.H., Pop-Busui R., Braffett B.H., Martin C.L., Cleary P.A., Albers J.W., Feldman E.L.; DCCT/EDIC Research Group. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med. 2012;29(7):937–944. doi: 10.1111/j.1464-5491.2012.03644.x..
DOI: 10.1111/j.1464-5491.2012.03644.x

Moghtaderi A., Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006;108(5):477–481. doi: 10.1016/j.clineuro.2005.08.003..
DOI: 10.1016/j.clineuro.2005.08.003

Singleton J.R., Bixby B., Russell J.W., Feldman E.L., Peltier A., Goldstein J., Howard J., Smith A.G. The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy. J Periph Nerv Syst. 2008;13(3):218–227. doi: 1111/j.1529-8027.2008.00180.x..
DOI: 1111/j.1529-8027.2008.00180.x

Vinik E., Hayes R.P., Oglesby A., Bastyr E., Barlow P., Ford-Molvik S.L., Vinik A.I. The development and validation of the Norfolk QOL-DN, a new measure of patients´ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2008;7(3):497–508. doi: 10.1089/dia.2005.7.497..
DOI: 10.1089/dia.2005.7.497

Hillienmark L., Alstrand N., Jonsson B., Ludvigson J., Cooray G., Wahlberg- Topp J. Early electrophysiological abnormalities and clinical neuropathy. Diabetes Care. 2013;36(10):3187–3194. doi: 10.2337/dc12-2226..
DOI: 10.2337/dc12-2226

Shin J.B., Seong Y.J., Lee H.J., Kim S.H., Suk H., Lee Y.J. The usefulness of minimal F-wave latency and sural/radial amplitude ratio in diabetic polyneuropathy. Yonsei Med J. 2000;41(3):393–397. doi: 10.3349/ymj.2000.41.3.393..
DOI: 10.3349/ymj.2000.41.3.393

Dyck P.J., Litchy W., Daube J.R., Harper M., Dyck J.B., Davies J., O’Brien P.C. Individual attributes versus composite scores of nerve conduction abnormality: sensitivity, reproducibility and concordance with impairment. Muscle Nerve 2003;27(2):202–210. doi: 10.1002/mus.10320..
DOI: 10.1002/mus.10320

Albers J.W., Brown M.B., Sima A.A.F., Greene D.A. Frequency of median nerve mononeuropathy in patients with mild diabetic polyneuropathy in the early diabetes intervention trial (EDIT). Muscle Nerve;1996;19(2):140–146. doi: 10.1002/(SICI)1097-4598(199602)19:2<140::AID-MUS3>3.0.CO;2-E..
DOI: 10.1002/(SICI)1097-4598(199602)19:2<140::AID-MUS3>3.0.CO;2-E

Horinouchi S., Deguchi T., Arimura K., Arimura A., Dochi Y., Uto T. et al. Median neuropathy at the wrist as an early manifestation of diabetic neuropathy. J Diabetes Invest. 2014:5(6):709–713. doi: 10.5455/medarh.2014.68.98-101..
DOI: 10.5455/medarh.2014.68.98-101

Sung J.-Y., Tani J., Chang T.-S., Lin C.S.-Y. Uncovering sensory axonal dysfunction in asymptomatic type 2 diabetic neuropathy. PLoS ONE. 2017;12(2):e0171223. doi: 10.1371/journal.pone.0171223..
DOI: 10.1371/journal.pone.0171223

Van der Heyden J.C., van der Meer P., Birnie E., de Coo F.M. et al. Decreased excitability of the distal motor nerve of young patients with type-1 diabetes mellitus. Pediatr Diabetes. 2013;14(7):519–525. doi: 10.1111/pedi.12048..
DOI: 10.1111/pedi.12048

American Diabetes Association, American Academy of Neurology. Report and recommendations of the San Antonio Conference on Diabetic neuropathy. Diabetes Care. 1988;11(7):592–597. doi: 10.2337/diacare.11.7.592..
DOI: 10.2337/diacare.11.7.592

Andresen H., Stalberg E., Falck B. F-wave latency, the most sensitive nerve conduction parameter in patients with diabetes mellitus. Muscle Nerve. 1997;20(10):1296–1302. doi: 10.1002/(SICI)1097-4598(199710)20:10<1296::AIDMUS12>3.0.CO;2-1..
DOI: 10.1002/(SICI)1097-4598(199710)20:10<1296::AIDMUS12>3.0.CO;2-1

Kohara N., Kimura J., Kaji R., Goyo Y., Ishii J., Takiguchi M., Nakai M. F-wave latency serves as the most reproductible measure in nerve conduction studies of diabetic polyneuropathy: multicenter analysis in healthy patients and patients with diabetic polyneuropathy. Diabetologia 2000;43:915–921. doi: 10.1007/s001250051469..
DOI: 10.1007/s001250051469

Pan H., Jian F., Lin J., Chen N., Zhang C., Zhang Z. et al. F-wave latencies in patients with diabetes mellitus. Muscle Nerve. 2014;49(6):804–808. doi: 10.1002/mus.24127..
DOI: 10.1002/mus.24127

Lachman T., Shahani B.T., Young R.R. Late responses as aids to diagnosis in peripheral neuropathies. J Neurol Neurosurg Psychiatry. 1980;43:156–162. doi: 10.1136/jnnp.43.2.156..
DOI: 10.1136/jnnp.43.2.156

Toopchizadeh V., Shiva S., Khiabani N.Y., Ghergherechi R. Electrophysiologic pattern and prevalence of subclinical peripheral neuropathy in children and adolescents with type-1 diabetes mellitus in Iran. Saudi Med J. 2016;37(3):299–303. Available at: https://www.pubfacts.com/detail/26905353/Electrophysiologic-pattern-and-prevalence-ofsubclinical-peripheral-neuropathy-in-children-and-adole.https://www.pubfacts.com/detail/26905353/Electrophysiologic-pattern-and-prevalence-ofsubclinical-peripheral-neuropathy-in-children-and-adole

Pozzessere G., Rossi P., Gabriele A., Cipriani R., Morocutti A., Di Mario U., Morano S. Early detection of small fiber neuropathy in Diabetes. Diabetes Care. 2000;25(12):2355–2357. doi: 10.2337/diacare.25.12.2355..
DOI: 10.2337/diacare.25.12.2355

Sumner C.J., Sheth S., Griffin J.W., Cornblath D.R., Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003;60(1):108–111. doi: 10.1212/wnl.60.1.108..
DOI: 10.1212/wnl.60.1.108

Yaman M., Uluduz D., Yuksel S., Pay G., Kiziltan M.E. The cutaneous silent period in diabetes mellitus. Neurosci Lett. 2007;419(3):258–262. doi: 10.1016/j.neulet.2007.04.018..
DOI: 10.1016/j.neulet.2007.04.018

Shy M.E., Frohman E.M., So Y.T., Arezzo J.C., Cornblath D.R., Giuliani M.J. et al. Quantitative sensory testing. Report of the therapeutics and technology assessment subcomitee of the American Academy of Neurology. Neurology. 2003;60(6):898–904. doi: 10.1212/01.wnl.0000058546.16985.11..
DOI: 10.1212/01.wnl.0000058546.16985.11

Tavakoli M., Petroupoulos I.N., Malik R.A. Corneal confocal microscopy to assess diabetic neuropathy. J Diabetes Sci Technol. 2013;7(5):1179–1189. doi: 10.1177/193229681300700509..
DOI: 10.1177/193229681300700509

Merita Tiric-Campara, Miro Denislic, Jasminka Djelilovic-Vranic, Azra Alajbegovic, Emir Tupkovic, Refet Gojak, Rok Zorec, Jasem Y. Al-Hashel. Cutaneous Silent Period in the Evaluation of Small Nerve Fibres. Med Arh. 2014 Apr; 68(2):98-101. doi: 10.5455/medarh.2014.68.98-101.
DOI: 10.5455/medarh.2014.68.98-101

Švilpauskaitė J., Truffert A., Vaičienė N., Magistris M.R. Electrophysiology of small peripheral nerve fibers in man. A study using the cutaneous silent period. Medicina (Kaunas). 2006;42(4):300–312. Available at: http://medicina.lsmuni.lt/med/0604/0604-06e.pdf.http://medicina.lsmuni.lt/med/0604/0604-06e.pdf

Koytac P.K., Isak B., Borucu D., Uluk K. Assessment of symptomatic diabetic patients with normal nerve conduction studies: utility of cutaneous silent period and autonomic tests. Muscle Nerve. 2011;43(3):317–323. doi: 10.1002/mus.21877..
DOI: 10.1002/mus.21877

Onal M.R., Ulas U.H., Oz O., Bek V.S., Yucel M., Talispinar A., Odabası Z. Cutaneous silent period changes in type-2 diabetes mellitus patients with small fiber neuropathy. Clin Neurophysiol. 2010;121(5):714–718. doi: 10.1016/j.clinph.2009.12.024..
DOI: 10.1016/j.clinph.2009.12.024

Braune H.J., Horter C. Sympathetic skin responses in diabetic neuropathy: a prospective clinical and neurophysiological trial on 100 patients. J Neurol Sci. 1996;138(1–2):120–124. doi: 10.1016/0022-510x(96)00023-8..
DOI: 10.1016/0022-510x(96)00023-8

Isak B., Oflazoglu B., Tanridag T., Yitmen I., Us O. Evaluation of peripheral and autonomic neuropathy among patients with newly diagnosed impaired glucose tolerance. Diabetes Metab Res Rev. 2008;24(7):563–569. doi: 10.1002/dmrr.859..
DOI: 10.1002/dmrr.859

Casellini C.M., Parson H.K., Richardson M.S., Nevoret M.L., Vinik A.I. SUDOSCAN, a non-invasive tool for detecting diabetic small fiber neuropathy and autonomic dysfunction. Diabetes Technol Ther. 2013;15(11):948–953. doi: 10.1089/dia.2013.0129..
DOI: 10.1089/dia.2013.0129

Mao F., Liu S., Qiao X., Zheng H., Xiong Q., Wen J. et al. Sudoscan is an effective screening method for asymptomatic diabetic neuropathy in chinese type-2 diabetes mellitus patients. J Diabetes Investig. 2017;8(3):363–368. doi: 10.1111/jdi.12575..
DOI: 10.1111/jdi.12575

Mayaudon H., Miloche P.O., Bauduceau B. A new simple method for assessing sudomotor function: Relevance in type-2 diabetes. Diabetes Metab. 2010;(6 Pt 1):450–454. doi: 10.1016/j.diabet.2010.05.004..
DOI: 10.1016/j.diabet.2010.05.004

Selvarajah D., Cash T., Davies J., Sankar A., Rao G., Grieg M. et al. SUDOSCAN: A simple, rapid and objective method with potential for screening for diabetic peripheral neuropathy. PloS ONE. 2015;10(10):e0138224. doi: 10.1371/journal.pone.0138224..
DOI: 10.1371/journal.pone.0138224

Smith A.G., Lessard M., Singleton J.R. The diagnostic utility of SUDOSCAN for distal symmetric peripheral neuropathy. J Diabetes Complications. 2014;28(4):511–516. doi: 10.1016/j.jdiacomp.2014.02.013..
DOI: 10.1016/j.jdiacomp.2014.02.013

Yajnik C.S., Kantikar V.V., Pande A.J., Deslypere J.P. Quick and simple evaluation of sudomotor function for screening of diabetic neuropathy. ISRN Endocrinol. 2012;2012:103714. doi: 10.5402/2012/103714..
DOI: 10.5402/2012/103714

Papanas N., Papatheodorou K., Papazoglou D., Christakidis D., Monastiriotis C., Maltezos E. The new indicator test: a valuable diagnostic tool for small fiber impairment in patients with type-2 diabetes. Diabetes Educ. 2007;33(2):251–258. doi: 10.1177/0145721707299661.
DOI: 10.1177/0145721707299661

Shimada H., Kihara M., Kosaka S., Ikeda H., Kawabata K., Tsutada T., Miki T. Comparison of SSR and QSART in early diabetic neuropathy – the value of length-dependent pattern in QSART. Auton Neurosci. 2001;92(1–2):72–75. doi: 10.1016/S1566-0702(01)00287-9..
DOI: 10.1016/S1566-0702(01)00287-9

Sommer P., Kluschina O., Scley M., Namer B., Schmelz M., Rukwied R. Electrically induced quantitative sudomotor axon test in human volunteers. Auton Neurosci. 2011;159(1–2):111–116. doi: 10.1016/j.autneu.2010.09.004..
DOI: 10.1016/j.autneu.2010.09.004

Ravits J.M. AAEM minimonograph #48: autonomic nervous system testing. Muscle Nerve. 1997;20(8):919–937. doi: 10.1002/(sici)1097-4598(199708)20:8<919::aid-mus1>3.0.co;2-9..
DOI: 10.1002/(sici)1097-4598(199708)20:8<919::aid-mus1>3.0.co;2-9

Guthoff R.F., Zhivov A., Stachs O. In vivo confocal microscopy, an inner vision of the cornea – a major review. Clin Expermient Ophtalmol. 2009;37(1):100–117. doi: 10.1111/j.1442-9071.2009.02016.x..
DOI: 10.1111/j.1442-9071.2009.02016.x

Azmi S., Ferdousi M., Petropoulos I.N., Ponirakis G., Alam U., Fadavi H. et al. Corneal comnfocal microscopy identifies small-fiber neuropathy in subjects with impaired glucose tolerance who develop type-2 diabetes. Diabetes Care. 2015;38(8):1502–1508. doi: 10.2337/dc14-2733..
DOI: 10.2337/dc14-2733

Lauria G., Lombardi R., Camozzi F., Devigli G. Skin biopsy for the diagnosis of peripheral neuropathy. Histopathology. 2009;54(3):273–285. doi: 10.1111/j.1365-2559.2008.03096.x..
DOI: 10.1111/j.1365-2559.2008.03096.x

Sommer C., Lauria G. Skin biopsy in the management of peripheral neuropathy. Lancet Neurol. 2007;6(7):632–642. doi: 10.1016/S1474-4422(07)70172-2..
DOI: 10.1016/S1474-4422(07)70172-2

Periquet M.J., Novak V., Collins M.P., Nagaraja H.N., Erdem S., Nash S.M. et al. Painful sensory neuropathy. Prospective evaluation using skin biopsy. Neurology. 1999;53(8):1641–1647. doi: 10.1212/wnl.53.8.1641..
DOI: 10.1212/wnl.53.8.1641

Saperstein D.S., Levine T.D. Diagnosing small fiber neuropathy through the use of skin biopsy. Pract Neurol. 2009;8:37–40. Available at: https://corinthianreferencelab.com/wp-content/uploads/2018/01/Pract_Neuro.pdf.https://corinthianreferencelab.com/wp-content/uploads/2018/01/Pract_Neuro.pdf

Herder C., Roden M., Ziegler D. Novel Insights into Sensorimotor and Cardiovascular Autonomic Neuropathy from Recent-Onset Diabetes and Population-Based Cohorts. Trends in Endocrinology and Metabolism. 2019;30(5):286–298. doi: 10.1016/j.tem.2019.02.007..
DOI: 10.1016/j.tem.2019.02.007

Zoppini G., Cacciatori V., Raimondo D., Gemma M., Trombetta M., Dauriz M. et al. The prevalence of cardiovascular autonomic neuropathy in a cohort of patients with newly diagnosed type-2 diabetes. The Verona Newly Diagnosed Type-2 Diabetes Study (VNDS). Diabetes Care. 2015;38(8):1487–1493. doi: 10.2337/dc15-0081..
DOI: 10.2337/dc15-0081

Rolim L.C., Sa J.R., Chacra A.R., Dib S.A. Diabetic cardiovascular autonomic neuropathy: risk factors, clinical impact and early diagnosis. Arq Bras Cardiol. 2008;90(4):e24–31. doi: 10.1590/s0066-782x2008000400014..
DOI: 10.1590/s0066-782x2008000400014

Zilliox L., Peltier A.C., Wren P.A., Anderson A., Smith A.G., Singleton J.R. et al. Assessing autonomioc dysfunction in the early diabetic neuropathy. The Survey of Autonomic Symptom. Neurology. 2011;76(12):1099–1105. doi: 10.1212/WNL.0b013e3182120147..
DOI: 10.1212/WNL.0b013e3182120147

Ishibashi F., Taniguchi M., Kojima R., Awasaki A., Kosaka A., Uetake H. Elasticity of the tibial nerve assessed by sonoelastography was reduced before the development of neuropathy and further deterioration associated with the severity of neuropathy un type-2 diabetes. J Diabetes Investig. 2016;7(3):404–412. doi: 10.1111/jdi.12408..
DOI: 10.1111/jdi.12408

Pitarokopilli K., Kerasnoudis A., Behredt V., Labedi A., Ayzenberg I., Gold R., Yoon M.-S. Facing the diagnostic challenge: Nerve Ultrasound in diabetic patients with neuropathic symptoms. Muscle Nerve. 2016;54(1):18–24. doi: 10.1002/mus.24981..
DOI: 10.1002/mus.24981

Vaeggemose M., Ringgaard S., Ejskjaer N., Andersen H. Magnetic Resonance Imaging may be used for early evaluation of diabetic peripheral neuropathy. J Diabetes Sci Technol. 2015;9(1):162–163. doi: 10.1177/1932296814559303..
DOI: 10.1177/1932296814559303

Pham M., Oikonomou D., Hornung B., Weiler M., Heiland S., Baumer P. et al. Magnetic resonance neurography detects diabetic neuropathy early and with proximal predominance. Ann Neurol. 2015;78(6):939–948. doi: 10.1002/ana.24524..
DOI: 10.1002/ana.24524

Choi A., Kim H.W., Kwon J.W., Shim Y.S., Jee D.H., Yun J.S. et al. Early inner retinal thinning and cardiovascular autonomic dysfunction in type-2 diabetes. PloS ONE. 2017;12(3):e0174377. doi: 10.1371/journal.pone.0174377..
DOI: 10.1371/journal.pone.0174377

Akbar M., Bhandari U., Habib A., Ahmad R. Potential association of triglyceride glucose index with cardiac autonomic neuropathy in type-2 diabetes mellitus patients. J Korean Sci. 2017;32(7):1131–1138. doi: 10.3346/jkms.2017.32.7.1131..
DOI: 10.3346/jkms.2017.32.7.1131

Scott L.A., Kench P.L. Cardiac autonomic neuropathy in the diabetic patient. Does 123I-MIBG imaging have a role to play in early diagnosis? Nucl Med Technol. 2004;32(2):66–71. Available at: http://tech.snmjournals.org/content/32/2/66.http://tech.snmjournals.org/content/32/2/66

Hattori N., Tamaki N., Hayashi T., Masuda I., Kudoh T., Tateno M. et al. Regional abnormality of Iodine-123-MIBG in diabetic hearts. J Nucl Med. 1996;37(12):1985–1990. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8970519.https://www.ncbi.nlm.nih.gov/pubmed/8970519

Schnell O., Hammer K., Muhr-Becker D., Ziegler AG, Weiss M., Tatsch K., Standl E. Cardiac sympathetic dysinnervation in type-2 diabetes mellitus with and without ECG-based cardiac autonomic neuropathy. J Diabetes Complications. 2006;16(3):220–227. doi: 10.1016/s1056-8727(01)00180-5..
DOI: 10.1016/s1056-8727(01)00180-5

Scholte A.J.H.A., Schvijf J.D., Delgado V., Kok J.A., Bus M.T.J., Maan A.C. et al. Cardiac autonomic neuropathy in patients with diabetes and no symptoms of coronary artery disease: comparison of 123I-metaiodobenzylguanidine myocardial scintigraphy and heart rate variability. Eur J Nucl Med Mol Imaging. 2010;37:1698–1705. doi: 10.1007/s00259-010-1442-0..
DOI: 10.1007/s00259-010-1442-0

Shakher J., Stevens M.J. Update on the management of diabetic polyneuropathies. Diabetes Metab Syndr Obes.2011;4:289–305. doi: 10.2147/DMSO.S11324..
DOI: 10.2147/DMSO.S11324

The Diabetes Control and Complications Trial research group: the effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122(8):561–568. doi: 10.7326/0003-4819-122-8-199504150-00001..
DOI: 10.7326/0003-4819-122-8-199504150-00001

Callaghan B.C., Little A.A., Feldman E.L., Hughes R.A.C. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;(6):CD007543. doi: 10.1002/14651858.CD007543.pub2..
DOI: 10.1002/14651858.CD007543.pub2

Zhoungas S., Arima H., Gerstein H.C., Holman R.R., Woodward M., Reaven P. et al. Effect of intensive glucose control on microvascular outcomes in patients with type-2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(6):431–437. doi: 10.1016/S2213-8587(17)30104-3..
DOI: 10.1016/S2213-8587(17)30104-3

Stino A.M., Smith A.G. Peripheral neuropathy in the prediabetes and the metabolic syndrome. J Diabetes Investig. 2017;8(5):646–655. doi: 10.1111/jdi.12650. 86. Smith A.G., Russell J., Feldman E.L., Goldstein J., Peltier A. et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29(6):1294–1299. doi: 10.2337/dc06-0224..
DOI: 10.2337/dc06-0224

Singleton J.R., Marcus R.L., Jackson J.E., Lessard M.K., Graham T.E., Smith A.G. Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Ann Clin Trans Neurol. 2014;1(10):844–849. doi: 10.1002/acn3.125..
DOI: 10.1002/acn3.125

Singleton J.R., Marcus R.L., Lessard M., Jackson J.E., Gordon Smith A. Supervised exercise improves cutaneous reinnervation capacity in metabolic syndrome patients. Ann Neurol. 2015;77(1):146–153. doi: 10.1002/ana.24310..
DOI: 10.1002/ana.24310

Khang S.J., Ko K.J., Baek U.H. Effect of 12 weeks combined aerobic and resistance exercise on heart-rate variability in type-2 diabetes mellitus patients. J Phys Ther Sci. 2016;28(7):2088–2093. doi: 10.1589/jpts.28.2088..
DOI: 10.1589/jpts.28.2088

Pennathur S., Jaiswal M., White E.A., Ang L., Raffel D.M., Rubenfire M., Pop- Busui R. Structured lifestyle intervention in patients with the metabolic syndrome mitigates oxidative stress but fails to improve measures of cardiovascular autonomic neuropathy. J Diabet Compl. 2017;31(9):1437–1443. doi: 10.1016/j.jdiacomp.2017.03.008..
DOI: 10.1016/j.jdiacomp.2017.03.008

Golbidi S., Badran M., Laher I. Diabetes and alpha lipoic acid. Front Pharmacol. 2011;2:69. doi: 10.3389/fphar.2011.00069..
DOI: 10.3389/fphar.2011.00069

Manning P.J., Sutherland W.H.F., Williams S.M., Walker R.J., Berry E.A., De Jong S.A., Ryalls A.R. The effect of lipoic acid and the vitamin E therapies in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2013;23(6):543–549. doi: 10.1016/j.numecd.2011.11.006..
DOI: 10.1016/j.numecd.2011.11.006

Namazi N., Larijani B., Azadbakht L. Alpha-lipoic acid supplement in obesity treatment: A systematic review and meta-analysis of clinical trials. Clin Nutr. 2018;37(2):419–428. doi: 10.1016/j.clnu.2017.06.002..
DOI: 10.1016/j.clnu.2017.06.002

Sun H., Yao W., Tang Y., Zhuang W., Wu D., Huang S., Sheng H. Urinary exosomes as a novel biomarker for the evaluation of a-lipoic acid´s protective effect in early diabetic nephropathy. J Clin Lab Anal. 2017;31(6):e22129. doi: 10.1002/jcla.22129..
DOI: 10.1002/jcla.22129

Han T., Bai J., Liu W., Hu Y. A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol. 2012;167(4):465–471. doi: 10.1530/EJE-12-0555..
DOI: 10.1530/EJE-12-0555

Mijnhout G.S., Kollen B.J., Alkhalaf A., Kleefstra N., Bilo H.J. Alpha Lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a metaanalysis of randomized controlled trials. Int J Endocrinol. 2012;2012:456279. doi: 10.1155/2012/456279..
DOI: 10.1155/2012/456279

Tankova T., Koev D., Dakovska L. Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study). Rom J Intern Med. 2004;42(2):457–464. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15529636.https://www.ncbi.nlm.nih.gov/pubmed/15529636

Ziegler D., Ametov A., Barinov A., Dyck P.J., Gurieva I., Low P.A. et al. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy. Diabetes Care. 2006;29(11):2365–2370. doi: 10.2337/dc06-1216..
DOI: 10.2337/dc06-1216

Ziegler D,, Schatz H,, Conrad F,, Gries F,A,, Ulrich H,, Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicentre trial (DEKAN Study). Diabetes Care. 1997;20(3);369–373. doi: 10.2337/diacare.20.3.369..
DOI: 10.2337/diacare.20.3.369

Grewal A.S., Bhardwaj S., Pandita D., Lather V., Sekhon B.S. Updates on Aldose Reductase Inhibitors for management of diabetic complications and non-diabetic diseases. Mini Rev Med Chem. 2016;16(2):120–162. doi: 10.2174/1389557515666150909143737..
DOI: 10.2174/1389557515666150909143737

Stacke H., Gaus W., Achenbach U., Federlin K., Bretzel R.G. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised doubleblind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 2008;116(10):600–605. doi: 10.1055/s-2008-1065351..
DOI: 10.1055/s-2008-1065351

Won J.C., Kwon H.S., Moon S.S., Chun S.W., Kim C.H. et al. γ-Linolenic Acid versus α-Lipoic Acid for Treating Painful Diabetic Neuropathy in Adults: A 12-Week, Double-Placebo, Randomized, Noninferiority Trial. Diabetes Metab J. 2019;43:e60. doi: 10.4093/dmj.2019.0099..
DOI: 10.4093/dmj.2019.0099

Keen H., Payan J., Allawi J. et al. Treatment of Diabetic Neuropathy With γ-Linolenic Acid. Diabetes Care 1993;16(1):8–15. doi: 10.2337/diacare.16.1.8..
DOI: 10.2337/diacare.16.1.8

Rolim L.C., da Silva E.M.K., Flumignan R.L.G., Abreu M.M., Dib S.A. Acetyl- L-carnitine for the treatment of diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews. 2019;(6):CD011265. doi: 10.1002/14651858.CD011265.pub2..
DOI: 10.1002/14651858.CD011265.pub2

Ziegler D., Movsesyan L., Mankovsky B., Gurieva I., Abylaiuly Zh., Strokov I. Treatment of Symptomatic Polyneuropathy With Actovegin in Type 2 Diabetic Patients. Diabetes Care. 2009;32(8):1479–1484. doi: 10.2337/dc09-0545..
DOI: 10.2337/dc09-0545

Дополнительная информация
Язык текста: Русский
ISSN: 2079-701X
Унифицированный идентификатор ресурса для цитирования: //medj.rucml.ru/journal/4e432d4d4544534f5645542d41525449434c452d323032302d302d372d302d35362d3635/